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Background: Previous studies have shown that long-term oral daily PDE 5 inhibitors (PDE5i) counteract fibrosis, cell
loss, and the resulting dysfunction in tissues of various rat organs and that implantation of skeletal muscle-derived
stem cells (MDSC) exerts some of these effects. PDE5i and stem cells in combination were found to be more
effective in non-MI cardiac repair than each treatment separately. We have now investigated whether sildenafil at
lower doses and MDSC, alone or in combination are effective to attenuate LV remodeling after MI in rats.
Methods: MI was induced in rats by ligature of the left anterior descending coronary artery. Treatment groups
were: “Series A”: 1) untreated; 2) oral sildenafil 3 mg/kg/day from day 1; and “Series B”: intracardiac injection at day
7 of: 3) saline; 4) rat MDSC (106 cells); 5) as #4, with sildenafil as in #2. Before surgery, and at 1 and 4 weeks, the left
ventricle ejection fraction (LVEF) was measured. LV sections were stained for collagen, myofibroblasts, apoptosis,
cardiomyocytes, and iNOS, followed by quantitative image analysis. Western blots estimated angiogenesis and
myofibroblast accumulation, as well as potential sildenafil tachyphylaxis by PDE 5 expression. Zymography
estimated MMPs 2 and 9 in serum.
Results: As compared to untreated MI rats, sildenafil improved LVEF, reduced collagen, myofibroblasts, and
circulating MMPs, and increased cardiac troponin T. MDSC replicated most of these effects and stimulated cardiac
angiogenesis. Concurrent MDSC/sildenafil counteracted cardiomyocyte and endothelial cells loss, but did not
improve LVEF or angiogenesis, and upregulated PDE 5.
Conclusions: Long-term oral sildenafil, or MDSC given separately, reduce the MI fibrotic scar and improve left
ventricular function in this rat model. The failure of the treatment combination may be due to inducing
overexpression of PDE5.
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Cardiac fibrosis is a major factor of tissue remodeling
during myocardial infarction (MI) recovery, heart failure,
ischemia reperfusion injury, and in most cardiomyopa-
thies [1]. The excessive extracellular matrix, together
with the activated fibroblasts and particularly myofibro-
blasts responsible for its deposition during tissue remod-
eling, impair the contractile function of the surviving
cardiomyocytes. Fibrosis may even affect the normal* Correspondence: ncadavid@ucla.edu
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reproduction in any medium, provided the orECM/fibroblast interaction in force networking around
myocytes and putative electrical coupling of both cell
types. The etiology, molecular/cellular pathology, pro-
gression, and impact on contractile tissue compliance of
cardiac tissue fibrosis, resemble the fibrosis occurring in
the arterial bed wall [2,3] and in vascular tissues such as
the kidney, skeletal muscle, urogenital organs [4-6], and
others, except for the cells that are affected and the
functional outcomes.
The current conventional therapy of MI, the modulators
of the renin-angiotensin-aldosterone system (RAAS), coun-
teracts fibrosis induced by angiotensin II in parallel to other
beneficial effects [7]. A novel antifibrotic and cardiomyo-
cyte protective therapy complementing hemodynamictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phosphodiesterase 5 inhibitors (PDE5i) [8,9], based ini-
tially on the cardiac preconditioning exerted by nitric
oxide and its main effector cGMP, presumably through in-
ducible nitric oxide synthase (iNOS) [10,11].
A recent study showed that the PDE 5 inhibitor silde-
nafil given intraperitoneally daily for 4 weeks after per-
manent left anterior descending (LAD) coronary artery
ligation attenuated the increase in left ventricular end-
diastolic diameter in the mouse, and improved fractional
shortening, overall survival, infarct size, and apoptotic
index [12]. The induction of eNOS and iNOS and reduc-
tion of apoptosis by this sildenafil treatment mediated by
cGMP-dependent protein kinase (PKG) was abrogated
in isolated mouse hearts by the inhibition of ERK phos-
phorylation [13].
Other studies demonstrated that sildenafil blunted
interstitial cardiac fibrosis in MI in the rat [14], that the
long-term sildenafil or vardenafil regimen exerted simi-
lar effects after ischemia reperfusion injury in rabbits
[15], and that tadalafil, a long acting PDE 5 inhibitor,
improved left ventricular function and survival during
doxorubicin-induced cardiotoxicity [16]. However, it is
difficult to compare most ischemia/reperfusion studies,
performed with single bolus treatment that exerts transi-
ent vasodilation, with chronic treatments modifying the
underlying cardiac histopathology. For instance, sildena-
fil in rats reduced infarct size at 24 hrs and cardiomyo-
cyte/endothelial apoptosis while increasing fractional
shortening and ejection fraction at 45 days [17]. The
same acute treatment in ischemia reperfusion/injury was
applied with tadalafil in mice and rats [18,19].
However, despite sildenafil is an approved treatment
for pulmonary hypertension in humans, some results
with PDE 5 inhibitors in animal models are inconsistent,
apparently dependent on the degree of experimental car-
diac stress and remodeling [20].
The antifibrotic effects of chronic treatment with PDE5i
that may occur on experimental left ventricle remodeling
after MI, resembling the process in non cardiac tissues.
Long-term, daily treatment with any one of the three PDE
5 inhibitors, as opposed to sporadic administration to in-
duce penile corporal vasorelaxation and thus erection,
prevents and even reverses corporal fibrosis in rat models
of vasculogenic erectile dysfunction, a sentinel of cardio-
vascular disease [21-23]. Clinical application of this
chronic PDE 5 inhibitor modality is being considered [24].
The antifibrotic action of PDE 5 inhibitors also operates in
rat models of bleomycin-induced pulmonary vascular fi-
brosis [25], diabetic nephropathy [26], and the Peyronie’s
fibrotic plaque [27].
PDE5i may be concurrently administered with stem
cells to increase the efficacy of adult stem cell therapy
for MI [28]. The combination of sildenafil and adipocytederived stem cells implanted into the left ventricle of
rats with dilated cardiomyopathy increased LVEF and
angiogenesis while decreasing cardiac oxidative stress,
apoptosis and fibrosis, as compared to the stem cells
alone [29]. In vitro pre-conditioning of the same stem
cells by sildenafil improved their cardiac repair efficacy
in mice with MI [30]. It is possible that PDE5i modulate,
through cGMP and PKG, stem cell lineage commitment
towards cardiomyocytes [31,32].
Mouse and human skeletal muscle derived stem cells
(MDSC) induce angiogenesis, reduce scar formation,
and improve LVEF, mainly through VEGF expression, in
mouse models of MI [33-35]. In rat models of MI,
MDSC were therapeutically superior to myoblasts and
comparable to bone marrow stem cells, although it is
unclear whether MDSC convert into cardiomyocytes
[36]. Skeletal myoblasts have a controversial experimen-
tal and clinical efficacy, whereas MDSC by being truly
pluripotent, and non-myogenically committed cells, are
more promising. However, there are no reports on
PDE5i modulation of MDSC.
In this study we aimed to investigate whether: a)
chronic daily treatment with oral sildenafil at low dose
in rats subjected to MI by permanent ligature of the
LAD coronary artery improves LVEF, and reduces colla-
gen deposition, myofibroblast accumulation, and loss of
cardiomyocytes in the left ventricle; b) intracardiac im-
plantation of MDSC affects similarly cardiac function
and remodeling, and sildenafil stimulates these effects.
Methods
Ethics
The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, National
Academy Press, Washington, DC, USA, revised 1996) and
was approved by the IACUC at LABioMed.
Animal procedures
Male Fisher 344 rats were either 3–4 months old
(MDSC isolation), or retired breeders (MI treatments),
from Harlan Sprague–Dawley Inc., San Diego, CA, USA
under aseptic conditions were anesthetized with isoflur-
ane, intubated, and ventilated to perform a left thoracot-
omy to expose the heart. MI was induced by permanent
ligation of the LAD coronary artery, about 2 mm from
the tip of the left auricle, using a 6/0 polypropylene su-
ture (Ethicon, Inc). The chest, muscle, and skin were
closed with standard procedures. Rats were allowed to
recover from anesthesia, subjected to procedures
below and then sacrificed at 4 weeks. Mortality dur-
ing surgery or for the following 2–3 days was about
30%, and only a couple of deaths occurred there-
after. Replacement rats were added to the study as
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was maintained, unless specified.
Rats (final n = 8/group) were randomly divided into
five groups: series A: untreated control (group 1); silde-
nafil (3 mg/kg/day) in the drinking water from day 1
(group 2); series B: aseptic intracardiac injection into the
penumbra at day 7, by repeating surgery to expose the
heart, of: 0.1 ml saline (group 3); rat MDSC (106 cells in
0.1 ml saline) labeled with the nuclear fluorescent stain
4',6-diamidino-2-phenylindole (DAPI) (group 4); MDSC
as group #4, complemented with sildenafil given from
day 7 as group #2 (group 5) (Figure 1)
Left ventricular ejection fraction (LVEF) was measured
at three stages: a) basal (before surgery); b) 1 week after
surgery; and c) before sacrifice, at 4 weeks. Anesthetized
animals in the supine or lateral decubitus position
were subjected to 2D and M-mode echocardiography
(15-MHz linear-array transducer system) under acous-
tic coupling gel.
MDSC isolation and culture
MDSC were prepared from the hind limb muscles from
the rat [33-36], using the preplating procedure, a vali-
dated standardized method for MDSC isolation [37], as
in our previous reports [38-40]. Tissues were dissociated
using sequentially collagenase XI, dispase II and trypsin,
and after filtration through 60 nylon mesh and pelleting,
the cells were suspended in Dulbecco’s Modified Eagle’s
Medium (DMEM) with 20% fetal bovine serum. Cells
were plated onto collagen I-coated flasks for 1 hr (pre-
plate 1 or pP1), and 2 hrs (preplate 2 for pP2), followed
by sequential daily transfers of non-adherent cells andFigure 1 Experimental protocol. Myocardial infarction (MI) was induced
Arrows indicate the time points for treatments with sildenafil alone, MDSC,
and measurement of various parameters (listed under each arrow), and finare-platings for 2 to 6 days, until preplate 6 (pP6). The
latter is the cell population containing MDSC. Cells
were then selected using magnetic beads coated with the
Sca 1 antibody. Cells were replicated on regular culture
flasks (no coating) and used in the 5th-10th passage, since
the mouse counterparts have been maintained in our
laboratory for at least 40 passages with the same, or even
increasing, growth rate. Flow cytometry was performed
to determine whether they were Sca 1+/CD34+/CD44+/
Oct 4 cells [40].
Detection and estimation in tissue sections
At 4 weeks, blood was extracted from anesthetized rats
and the animals were sacrificed. The right ventricle and
great vessels were trimmed from the heart and the left
ventricles were sliced transversally from apex to base
into 4 similar height slices numbered from 1 through 4.
Slices #2 contained the infarction area and site of MDSC
injection and its top ½ region was cryoprotected, embed-
ded in OCT, and used for cryosectioning around the site
of cell implantation. The remainder was fixed in 10%
formaldehyde fixation for paraffin embedding. In both
cases, transverse sections were obtained from apex to
base (8 μm). The other left ventricular slices were frozen
in liquid nitrogen and stored at −80°C.
The MI area was determined by staining frozen sec-
tions with Picro Sirius red, using computerized planim-
etry for the calculation of the % of infarcted left ventricle
[17]. Immunohistochemistry in paraffin-embedded sec-
tions was performed [17,28,38-40] for: a) myofibroblasts
by α-smooth muscle actin (ASMA) with anti human
mouse monoclonal in Sigma kit, 1:2 (Sigma Chemical,in rats by left anterior descending coronary artery (LAD) ligation.
and MDSC+ sildenafil, performance of surgical procedure,
l sacrifice.
Wang et al. Journal of Translational Medicine 2012, 10:159 Page 4 of 11
http://www.translational-medicine.com/content/10/1/159St Louis, MO, USA); b) apoptotic index by the TUNEL re-
action with the Apoptag kit (Millipore, Billerica, MA,
USA); and c) rabbit polyclonal anti-iNOS (Calbiochem/
EMD, Brookfield, WI, USA). Cardiomyocyte loss was esti-
mated with a monoclonal antibody against Troponin T-C
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
primary antibodies were detected by the biotinylated anti-
mouse IgG (Vector Laboratories, Burlingame, CA, USA),
the ABC complex containing avidin-linked horseradish
peroxidase (1:100; Vector Laboratories), and 3,3' diamino-
benzidine, and counterstaining with hematoxylin. For
detecting the implanted DAPI-labeled MDSC, frozen sec-
tions were stained for Troponin T, but following with a
biotinylated secondary anti-mouse IgG antibody (goat,
1:200, Vector Laboratories) and streptavidin-Texas Red.
The sections were viewed under an Olympus BH2
fluorescent microscope, and quantitative image analysis
was performed with ImagePro-Plus 5.1 software (Media
Cybernetics, Silver Spring, MD, USA) coupled to a Leica
digital bright field/fluorescence microscope/VCC video
camera. After images were calibrated for background
lighting, integrated optical density (IOD=area x average
intensity) was calculated. 6–7 fields were measured per
tissue section, with 3–4 sections per specimen, and 8 spe-
cimens per group.
Protein detection and estimations in tissue homogenates
Homogenates from left ventricular region #3 below the
infarcted area were obtained in boiling lysis buffer
(1% SDS, 1 mM sodium orthovanadate, 10 mM Tris pH
7.4 and protease inhibitors), and centrifuging at 16,000 g
for 5 min [38-40]. 5–30 μg of protein were run on 4-15%
polyacrylamide gels, and submitted to transfer and immu-
nodetection with the antibodies against Troponin T as
above, and the additional ones: calponin, mouse monoclo-
nal (Santa Cruz); ASMA, mouse monoclonal (Calbiochem,
EMD, San Diego, CA, USA); Von Willebrand factor, rabbit
polyclonal (Abcam Inc, Cambridge, MA); PDE5, rabbit
polyclonal (Calbiochem); GAPDH, mouse monoclonal
(Chemicon, Temecula, CA, USA). Membranes were incu-
bated with secondary polyclonal horse anti-mouse or
anti-rabbit IgG linked to horseradish peroxidase (1:2000;
BD Transduction Laboratories, Franklin Lakes, NJ, or
1:5000, Amersham GE, Pittsburgh, PA, USA) and bands
were visualized with luminol (SuperSignal West Pico,
Chemiluminescent, Pierce, Rockford, IL, USA). Quantita-
tive estimation was performed by densitometry, establish-
ing the ratio between the band intensities of each protein
against the reference GAPDH value.
Zymography for MMPs
A serum dilution (5 μg protein) was mixed with equal
volumes of zymography sample buffer (125 mM Tris–
HCl, pH 6.8, 50% glycerol, 8% SDS, 0.02% bromophenolblue), loaded onto 10% polyacrylamide zymogram gels
containing gelatin or casein (BioRad), and electrophor-
esed with 2.5 mM Tris–HCl, 19.2 mM glycine, 0.01%
SDS, pH 8.3, at 100 V [41]. The gels were then equili-
brated for 30 min at room temperature with renaturing
buffer (2.5% Triton). Zymograms were developed over-
night at 37°C in developing buffer, 50 mM Tris–HCl, pH
7.5, 200 mM NaCl, 5 mM CaCl2, 0.02% Brij-35. Gels
were stained with 0.5% Coomassie Blue for 1 hr, destained
with methanol/glacial acetic acid/water (50:10:40), rehy-
drated in the 5:7:88 mix, and dried. Areas of MMP activity
appeared as clear bands. Zymograms intensities were ana-
lyzed using NIH Image J.Drugs
The following drugs were used: buprenorphine (Reckitt
&Colman Products, England) and carprofen (Pfizer,
USA) for postoperative pain relief; and sildenafil (Pfizer,
USA) dissolved in the drinking water [21-23].Statistical analysis
All results are expressed as mean± standard error of the
mean (SEM). The normality distribution of the data was
established using the Wilk–Shapiro test. Multiple com-
parisons were analyzed by a single factor ANOVA,
followed by Newman–Keuls multiple comparison test.
Differences among groups were considered statistically
significant at P < 0.05.Results
Effects of chronic sildenafil
We first tested the effects of sildenafil on MI in the
rat, at a 3 mg/kg/day given in the drinking water. Figure 2
top shows that this dose moderately (30%) improved the
LVEF over the one in the untreated rats (36.6 ± 3.5 vs.
47.8± 4.1), and reduced to the same extent the infarction
size measured at 4 weeks by quantitative immunohisto-
chemistry for collagen fibers with Picro Sirius red
(16.4 ± 0.66 vs. 11.32± 1.07), in a region corresponding to
the area mainly affected by the LAD occlusion (region #2)
(Figure 2 bottom).
The antifibrotic effects of this dose of sildenafil in the
rat were confirmed by the considerable 73% reduction of
myofibroblasts (13.8 ± 1.5 vs. 3.9 ± 0.4), in the same left
ventricular region denoted by ASMA immunostaining
(Figure 3 top). iNOS was expressed in this region, as it
occurs in most fibrotic processes, but its levels remained
unchanged after sildenafil treatment (not shown). There
was a non-significant increase by sildenafil on the tropo-
nin T content in the same region of the left ventricle








































Figure 2 Long-term oral sildenafil improved left ventricular
function and reduced infarction size after LAD occlusion.
Sildenafil was given continuously for 4 weeks in the drinking water
(3 mg/kg/day) (n = 8/group). Top: The LVEF was measured before MI
(basal), and at 1 and 4 weeks. UT: untreated control; S: sildenafil.
Middle: representative micrographs (4 X) for the histochemical
detection of collagen by Picrosirius red in paraffin-embedded
sections. Bottom: quantitative image analysis of infarction area.
Statistical differences are stated for untreated versus basal, and






































Figure 3 Long-term oral sildenafil reduced myofibroblast
accumulation in the infarction area, but did not significantly
counteract the cardiomyocyte loss in this region. (n = 8/group).
Paraffin-embedded sections were used. Top: quantitative image
analysis of myofibroblasts by immunohistochemistry for ASMA.
Middle: representative micrographs for the immunohistochemical
detection of troponin T. Bottom: quantitative image analysis of
troponin T. UT: untreated control; S: sildenafil; ***p < 0.005.
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with sildenafil
The intracardiac implantation of homologous (rat) MDSC
into the infarcted heart, one week after LAD, improved
considerably (50%) LVEF over the value in the saline
injected rats (34.6 ± 3.8 vs. 51.9± 9.1), (Figure 4 top). How-
ever, contrary to expectations, the combination of this
treatment with sildenafil at the time of MDSC implant-
ation abrogated the beneficial effects of the cell therapy
against the same control (32.6 ± 4.2). This was paralleled
by the contrast between a 34% reduction in collagen de-
position in the infarcted area in the region around cell im-
plantation exerted by MDSC (15.2 ± 1.7 vs. 9.9 ± 0.7), and
the essential disappearance against the same control of
this beneficial effect when sildenafil was given concur-
rently (13.2 ± 1.6), (Figure 4 bottom).
The DAPI-labeled nuclei of the implanted MDSC per-
sisted after 4 weeks in the infarction region and were
mostly from cells engrafted in the interstitial connective
tissue. A few appeared to overlap the cardiomyocytes
identified by troponin T immunofluorescence staining,but this is insufficient to ascertain whether MDSC con-
verted into cardiomyocytes (Figure 5 top). There was a
non-significant increase in troponin T in the left ven-
tricle by MDSC, and a higher (30%) and significant in-
crease by the combination of MDSC and sildenafil, as
measured by quantitative immunohistochemistry in
comparison to the saline injected control (347 ± 99 and
474 ± 27 vs. 227 ± 24) (Figure 5 middle). Matching this
cardiomyocyte protection, the apoptotic index was
reduced by MDSC by 49% and to virtually negligible
levels by the combination with sildenafil (2.5 ± 0.2 and
0.2 ± 0.1 vs. 4.9 ± 0.2) (Figure 5 bottom).
The modest increase in troponin seen in the infarction
area (region #2) by the treatment with MDSC or
MDSC+ sildenafil was accompanied by an approximately
25% increase in the expression of the 41 kDa troponin
band estimated by western blot in the adjacent non
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Figure 4 Intracardiac implantation of MDSC improved the LVEF
and reduced infarction size after LAD, but concurrent chronic
sildenafil abrogated these effects. Intracardiac injection of saline
or MDSC was conducted at 1 week (n = 7/group). Sildenafil was then
given continuously in the drinking water until sacrifice at 4 weeks.
Top: Ejection fraction before MI (basal), and at 1 and 4 weeks.
NaCl: control injected with saline; MDSC: injection with MDSC;
MDSC+ S: MDSC with sildenafil. Bottom: quantitative image analysis
of infarction area by Picrosirius red histochemistry. Statistical
differences are stated for untreated versus basal, and MDSC, and
MDSC+ sildenafil versus untreated; *p < 0.05.
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Figure 5 MDSC implanted in the MI area survived after 4 weeks
and reduced the apoptotic index, in a process stimulated by
sildenafil that also partially counteracted the cardiomyocyte
loss. (n = 7/group). Top: representative picture of frozen sections
from MI regions that received DAPI-labeled MDSC, visualized with
blue (DAPI) and red (Texas red) fluorescence filters for implanted
nuclei and troponin-T stained cardiomyocytes, respectively. Arrows:
cardiomyocyte/MDSC nuclei overlapping. Middle and lower panels:
quantitative image analysis by Troponin T and TUNEL (apoptosis)
immuno-histochemistry in paraffin-embedded sections, respectively.
Abbreviations as in Figure 4. Statistical differences are stated for
untreated versus basal, and MDSC, and MDSC+ sildenafil versus
untreated; *p < 0.05; **p < 0.01;***p< 0.005.
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In contrast, there was a significant increase by MDSC of
the smooth muscle cells (SMC) (1.0 ± 0.1 vs. 0.4 ± 0.1),
and endothelial cells (0.9 ± 0.1 vs. 0.7 ± 0.1), represented
respectively by calponin and von Willebrand proteins,
as an indication of angiogenesis (Figure 6). Although
MDSC+ sildenafil treatment increased endothelial con-
tent, it did not affect significantly calponin. In turn,
ASMA expression, a marker of myofibroblasts also shared
by SMC was increased by MDSC (1.2± 0.2 vs. 0.3 ± 0.1),
and sildenafil supplementation only slightly increased
ASMA. However, none of the treatments changed signifi-
cantly the arbitrary, relative ASMA/calponin ratio (1.2
and 0.9 respectively, vs. 0.9 in the control), thus sug-
gesting that the myofibroblast content in region #3
was not changed.
To investigate whether some of the effects exerted by
concurrent sildenafil could be due to an increase in PDE 5
protein that would counteract the inhibition of its activity
by the drug, PDE 5 was also estimated (Figure 6). That
this was the case was shown by the significant increase of
PDE 5 levels by MDSC+ sildenafil, but not by MDSC
alone in comparison to the saline injected rats (1.7 ± 0.3
and 1.2 ± 0.2, respectively, vs. 0.6 ± 0.2). PDE 5 expression
was also detected in the MDSC in culture. The magnitudeof all the observed changes by western blot assays in the
area adjacent to the infarct is likely lower than in region
#2 used for histochemical evaluation of the infarct area.
The relative effects of sildenafil or MDSC alone, or in
combination, on left ventricle remodeling were also
assessed by determining the release of MMPs to the circu-
lation, using zymography to estimate the levels of the pro-
enzymes and processed MMPs. Only the gelatinases
MMP-2 and −9 were detected in serum. MDSC reduced
significantly the levels of serum pro-MMP-2 (7.0± 1.6 vs.
14.8± 1.6) and −9 (1.7± 1.7 vs. 8.9 ± 2.6) and of active
MMP-9 (1.7± 1.1 vs. 8.7 ± 2.5) in comparison to the saline
injection, but the concurrent administration of sildenafil
did not alter these effects (Figure 7).
MDSC in culture
PDE5 













































Figure 6 Implanted MDSC stimulated angiogenesis and reduced myofibroblasts, without affecting PDE 5 expression, while concurrent
sildenafil protected the endothelium but increased myofibroblasts and upregulated PDE5. (n = 7/group). Protein extracts were obtained
from region #3 adjacent to the infarction area and subjected to western blot analysis. A: representative immunoblots (n = 8), indicating band
sizes. B: PDE 5 assayed in MDSC cultures in duplicate. C: Densitometric values corrected by GAPDH. Statistical differences are stated for untreated
versus basal, and MDSC, and MDSC+ sildenafil versus untreated; *p < 0.05; **p < 0.01;***p< 0.005.
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This study aimed to address the issue on whether con-
current long-term daily administration of low doses of
oral PDE 5 inhibitors, compatible with standard on de-
mand clinical use, can stimulate the potential antifibrotic
and antiapoptotic effects of stem cells, in this case
MDSC, on MI repair, thus extending to this condition
prior similar studies with PDE 5 inhibitors alone on the
vascular bed and in urological organs, and even in avas-
cular tissues [6,16,21-23,27]. First, we have shown that
oral sildenafil given alone (no MDSC) to the rat for
4 weeks post-MI, acts as expectedly, by moderately in-
creasing the LVEF and troponin recovery in tissue sec-
tions in the left ventricular region around the infarction,
and reducing the fibrotic area and myofibroblast infiltra-
tion. Second, MDSC given alone (no sildenafil) actedsimilarly, while also reducing apoptosis measured by
TUNEL, enhancing angiogenesis (SMC content) assayed
by western blot, and lowering tissue remodeling as indi-
cated by pro-MMP 2 and 9 and active MMP 9 levels in
serum. Third, the concurrent long-term administration
of MDSC+ sildenafil to rats with MI intensified as
expected the antiapoptotic, and cardiomyocyte and
endothelial protective effects of the separate MDSC and
sildenafil treatments, and preserved the serum MMP pat-
tern of the rats receiving MDSC.
However, unexpectedly the MDSC+ sildenafil combin-
ation treatment inhibited the improvement of the LVEF
and the reduction of the fibrotic area by MDSC or silde-
nafil alone, and the increased angiogenesis (measured by
SMC content) by MDSC. We postulate that this abroga-
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Figure 7 Implanted MDSC reduced left ventricular remodelling, as indicated by the decrease of both pro MMP-2 and 9 in serum, and
concurrent long-term oral sildenafil, did not modified these effects. MMPs were analyzed by zymography (n = 7/group). The Y axes indicate
relative densitometric intensities. Abbreviations as in Figures 1 and 3; *p < 0.05.
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by each independent treatment is due in part to the
observed upregulation of PDE 5 expression (that would
counteract the inhibition of PDE 5 enzyme activity by
sildenafil alone).
The dose of oral sildenafil for the current rat study,
3 mg/kg/day, was selected to be clinically translatable to
humans, and also to be compatible with the goal of
modulate the differentiation of stem cells given concur-
rently [42]. It is double the daily dose given for 4 weeks
either IP for MI in the mouse [12], or orally, concurrent
with MDSC, as antifibrotic in the rat corpora cavernosa
[43]. This dose comparison is likely to be reflected in the
respective sildenafil blood concentrations, since neither
the oral vs. IV or IP administration [44] nor the smalldifference in rat/mouse surface/weight ratios [45] are
expected to affect considerably the proportional pharma-
cokinetics. Translated to the human based on the rat/
human surface correction factor [21,23,45], our oral dose
would be roughly equivalent to about 30–40 mg/day,
or slightly less than the usual oral dose given sporadically
on demand to induce penile erection through corpora
cavernosal vasodilation. Other studies on MI in the rat [14]
have used much higher doses of sildenafil (100 mg/kg/day),
but when they are translated to human treatment they ex-
ceed considerably (more than tenfold) the clinical doses.
The beneficial effects of PDE5is for experimental is-
chemia/reperfusion, cardiac hypertrophy, and heart fail-
ure [9-19,46] have been ascribed to mechanisms as
varied as nitric oxide generation by upregulation of
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mitochondrial ATP-sensitive potassium channels, or in-
hibition of the RhoA-Rho kinase pathway in cardiac tissue,
or even distal effects reducing peripheral resistance and
aortic and large artery stiffness. However, we believe that
the improvement of the LVEF by our selected chronic
daily dose of sildenafil resulted from the expected antifi-
brotic action of PDE5is that replicated the inhibition of
collagen deposition, myofibroblast accumulation, and the
preservation of key functional cells under various tissue
damage conditions previously described in non cardiac
tissues [4,6,21-23,27]. This is essentially due to the in-
hibition of collagen synthesis, and myofibroblast dif-
ferentiation, and in certain cases, of apoptosis that by
counteracting fibrosis not only helps to protect the
normal cardiac tissue composition, but also the nor-
mal ECM/fibroblast interaction in force networking
around the myocytes and putative electrical coupling
of both cell types [1].
Our results on the reduction of MI scar size coincide
with the two long-term experimental studies of cardiopro-
tection in mice and rats after permanent LAD occlusion by
PDE5i given IP [12,17]. The caveat is that in the latter stud-
ies measurements were done at 24 hrs when the effects are
due to rapid vasodilation and related mechanisms instead
of the long-term antifibrotic action. Myofibroblast accumu-
lation, troponin T loss, angiogenic markers, or MMPs in
serum were not reported in those papers.
The lack of intensification of iNOS expression in the
rat post-MI cardiac tissue by sildenafil does not agree
with what was observed in the mouse in this condition
and in ischemia reperfusion injury [12,13], and even in
other organs [21-23], suggesting that studies on the time
course of iNOS blockade or overexpression on the cardi-
oprotective effects of chronic sildenafil in MI are needed
to clarify these discrepancies. This is of interest, consid-
ering that although in other tissues fibrosis was exacer-
bated by blocking iNOS by long-term administration of
the iNOS inhibitor L-NIL or by its genetic inactivation
in the iNOS ko mouse [4,46,47], in MI the role of iNOS
in fibrosis, vis-à-vis eNOS, is confusing, as evidenced by
various reports claiming deleterious, protective, or no
effects [47]. This may result from the opposite actions of
iNOS in the early inflammatory remodeling phase as
compared to the subsequent fibrogenesis.
The improvement of cardiac function, reduction of fi-
brotic scar, and cardiomyocyte preservation by MDSC
implantation into the MI area are in agreement with
previous results in mice [33-35] and in rats [36], al-
though it is not clear whether there is some conversion
of the engrafted cells into cardiomyocytes that does
occur with myoblasts or satellite cells, or this is exclu-
sively due to trophic effects such as the stimulation of
angiogenesis. The latter seems to have occurred in thepresent work, as judged by the observed increase in
SMC and endothelial markers.
The common denominator of these effects of sildenafil
is the expression of PDE5 in both the human left and
right ventricle, specifically in smooth muscle and endo-
thelial cells, and in the cardiomyocytes themselves,
which is considerably increased in end-stage ischemic
cardiomyopathy, and the assumption that this may con-
tribute to at least right ventricular heart failure [20]. The
observed upregulation of PDE5 in the MDSC/long-term
sildenafil combination may explain the loss of efficacy of
MDSC in improving LVEF and reducing scar size, since
this may cause tachyphylaxis [20,48]. This PDE5 upregu-
lation has been postulated to occur in the penile smooth
muscle due to the presence of cGMP-responsive ele-
ments in the PDE5 gene promoter [49], but has not been
observed in vivo [50]. Our assumption would require on
one side that sildenafil modulates MDSC lineage com-
mitment towards a fibrotic phenotype and myofibroblast
formation, and on the other side that the PDE5 upregu-
lation itself occurs in the MDSC or their differentiation,
since in the absence of MDSC sildenafil was moderately
effective. The MDSC myofibroblast differentiation was
suggested previously [51], assuming that the release of
local environmental stimuli after muscle injury triggers
the differentiation of MDSC into fibrotic cells, thus illus-
trating the importance of controlling the local environ-
ment within the injured tissue to optimize regeneration
via the transplantation of stem cells. We have shown this
differentiation in vitro [40]. This process also occurs
with mesenchymal cells, even in the absence of injury
[52]. Moreover, endogenous cardiac stem cells originate
fibroblasts, which are essential for proper tissue repair,
but also myofibroblasts whose accumulation may lead to
inadequate scar formation [53]. In turn, sustained high
cGMP levels induced by PDE5is, in the absence of PDE5
upregulation, reduced myoblast formation [54], so that
the reverse, i.e. the decrease of cGMP by high PDE5,
may trigger this differentiation. It is of interest that silde-
nafil was effective in potentiating the efficacy of adipose-
derived mesenchymal stem cells on cardiac repair in rat
dilated cardiomyopathy [29], but it reduced the efficacy of
MDSC in tissue repair, in this case in corporal penile fi-
brosis and loss of SMC subsequent to nerve damage [43],
suggesting that various types of stem cells may react dif-
ferently to PDE5i in terms of their repair capacity.
Altogether our results confirm in the rat that daily oral
sildenafil at low dose and MDSC exert separately a mod-
est cardioprotection post-MI by ameliorating the infarc-
tion scar formation and remodeling, but the in vivo
combination of these treatments, at least in the rat, is
counteractive. Further research is needed to identify sil-
denafil regimens that may not induce the PDE5 upregu-
lation, or alternatively by overriding the higher PDE5
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vitro preconditioning of stem cells with PDE5i prior to
implantation has just been shown, in this case with silde-
nafil and adipose-derived stem cells, to reduce in the
mouse post-MI cardiomyocyte apoptosis and fibrosis,
possibly by improving stem cell survival and paracrine
effects by secretion of growth factors [30] . This strategy
would avoid the in vivo sildenafil/stem cell interaction in
the host cardiac tissue setting, while preserving the
beneficial effects on stem cell trophic effects and/or
lineage commitment, even in the absence of a direct
protective action by sildenafil on cardiac tissue.
The design of the current work was restricted to the five
arms already described, in order to simplify it. However,
once the sildenafil dosages and times of administration are
optimized, the selected treatment should be compared
with the conventional RAAS therapy [7,55,56]. This may
involve an angiotensin II type I receptor blocker or a type
2 receptor stimulator, or an angiotensin-converting en-
zyme inhibitor, based on their well known antifibrotic,
anti-inflammatory, and cardiomyocyte protection effects,
and also in combination with MDSC. In fact, it is known
that RAAS modulators can inhibit or stimulate cardiovas-
cular progenitor functions, even if the overall picture is
not yet clear [57]. For instance, although AT(1) receptor
blockade and ACE inhibition stimulate proliferation and
differentiation of endothelial progenitor cells (EPC) and
angiogenesis, Ang-(1–7) that behaves similarly towards
EPC may either inhibit or stimulate angiogenesis accord-
ing to dosages. There are no reports on the modulation of
implanted stem cells by these agents. Similarly, no studies
with a RAAS/PDE5i combination have been reported,
even if combo approaches in the absence of stem cells
with AT(1) blockers and ACE inhibitors are being tested
[58]. Therefore, the optimal MDSC/sildenafil combination
should also be tested against an MDSC/RAAS combin-
ation to assess which antifibrotic/pro-differentiation ap-
proach may be more efficacious.
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